Bioventus Inc.
BVS
$9.15
-$0.36-3.79%
| 12/31/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.89% | 10.40% | 5.14% | 1.72% | 0.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.89% | 10.40% | 5.14% | 1.72% | 0.04% |
| Cost of Revenue | 0.49% | -1.87% | -4.84% | -2.44% | 1.72% |
| Gross Profit | 18.29% | 17.65% | 11.00% | 4.06% | -0.87% |
| SG&A Expenses | 8.02% | 5.65% | -1.03% | -7.78% | -8.51% |
| Depreciation & Amortization | -13.46% | -3.59% | 0.21% | -1.80% | -9.29% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.76% | 2.11% | -3.27% | -7.12% | -6.67% |
| Operating Income | 1,808.93% | 367.02% | 267.14% | 176.19% | 105.85% |
| Income Before Tax | 59.44% | 60.20% | 77.15% | 90.35% | 35.93% |
| Income Tax Expenses | -6,327.06% | 34.90% | 83.65% | 102.89% | 100.19% |
| Earnings from Continuing Operations | 63.83% | 62.10% | 76.00% | 88.20% | 16.21% |
| Earnings from Discontinued Operations | -- | 100.00% | 100.00% | 100.00% | -8.59% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -57.92% | -62.46% | -78.25% | -90.43% | -39.95% |
| Net Income | 78.53% | 78.31% | 85.17% | 92.45% | 1.56% |
| EBIT | 1,808.93% | 367.02% | 267.14% | 176.19% | 105.85% |
| EBITDA | 50.30% | 30.35% | 40.86% | 74.09% | 98.93% |
| EPS Basic | 79.18% | 78.94% | 85.57% | 92.57% | 2.47% |
| Normalized Basic EPS | 4,267.50% | 141.29% | -71.25% | -165.49% | 108.13% |
| EPS Diluted | 79.18% | 78.94% | 85.57% | 92.57% | 2.47% |
| Normalized Diluted EPS | 4,267.50% | 141.29% | -71.25% | -165.49% | 108.13% |
| Average Basic Shares Outstanding | 3.01% | 2.55% | 2.05% | 1.88% | 2.05% |
| Average Diluted Shares Outstanding | 3.01% | 2.55% | 2.05% | 1.88% | 2.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
